BioElectronics Corporation announced the commercial launch of its ActiPatch pain therapy device in Taiwan through distributor Aphrodite Medical Group, marking a significant expansion of drug-free pain management options in the Asian market. The US FDA-cleared medical device delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level, providing up to 720 hours of continuous therapy designed for extended wear including during sleep.
The initial shipment of ActiPatch units has been completed, positioning the device for a coordinated market launch in the second quarter of 2026. Aphrodite Medical Group, a well-established healthcare provider in Taiwan with a broad clinical footprint, will lead market introduction, physician engagement, and patient access initiatives across its network and affiliated channels. The rollout will initially focus on musculoskeletal pain management, with opportunities for expansion across additional clinical applications over time.
‘The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan,’ said Kelly Whelan, CEO of BioElectronics Corporation. ‘Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way.’ The Taiwan launch reinforces BioElectronics’ strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies.
Yang Pei-Hsien, Vice President of Aphrodite Medical Group, stated, ‘We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies. This technology aligns with the growing demand for safe, effective, and drug-free pain management options.’ The expansion comes as healthcare systems worldwide seek alternatives to pharmaceutical pain management, particularly amid concerns about opioid dependency and side effects associated with traditional pain medications.
ActiPatch represents a non-invasive approach to pain management that operates without pharmaceuticals, potentially reducing medication-related complications and offering patients a wearable solution that can be used continuously. The device’s clearance by the US Food and Drug Administration provides regulatory validation for its safety and efficacy, while its extended wear capability addresses practical concerns about treatment adherence in chronic pain management. More information about the company can be found at https://www.newmediawire.com.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is BioElectronics Corporation Launches ActiPatch Pain Therapy Device in Taiwan Through Aphrodite Medical Group.